LI
ADVM

Leap Investments’s Adverum Biotechnologies ADVM Stock Holding History

Leap Investments’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,620
Closed -$158K – 391
2020
Q1 		$158K Buy
+1,620
New +$189K 0.23% 194
2019
Q4 		– Sell
-2,269
Closed -$124K – 408
2019
Q3 		$124K Buy
+2,269
New +$256K 0.06% 350

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Leap Investments's ADVM Position: Q2 2020 in Review

Leap Investments sold out of Adverum Biotechnologies (ADVM) in Q2 2020, closing a stake of 1,620 shares — an estimated $158K sold.

Leap Investments first reported a position in ADVM in Q3 2019 and held it in 2 quarters. The position peaked at $158K in Q1 2020. 141 funds tracked by Wall St. Rank hold ADVM as of Q2 2020.

  • Leap Investments reported no remaining Adverum Biotechnologies position as of Q2 2020 after selling out during the quarter.
  • Leap Investments sold 1,620 Adverum Biotechnologies shares in Q2 2020, an estimated $158K.
  • Leap Investments first reported a position in Adverum Biotechnologies in Q3 2019 and held it in 2 quarters.
  • Leap Investments's Adverum Biotechnologies position peaked at $158K in Q1 2020.
  • 141 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.